Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Bortezomib is active in mantle cell lymphoma (MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase II study to evaluate the safety an...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Haematol
Main Authors: Till, Brian G., Li, Hongli, Bernstein, Steven H., Fisher, Richard I., Burack, W. Richard, Rimsza, Lisa M., Floyd, Justin D., DaSilva, Marco A., Moore, Dennis F., Pozdnyakova, Olga, Smith, Sonali M., LeBlanc, Michael, Friedberg, Jonathan W.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4710555/
https://ncbi.nlm.nih.gov/pubmed/26492567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13818
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki